KORU Medical Systems, Inc. KRMD R2K
Company Overview
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.
Why Investors Should Care
Net profit has compounded at 23.2% per year over the last five years.
Revenue has grown at a 13.8% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.20.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $41.13M (+22.2% YoY); net profit $-2.64M.
- Trailing 12 Months Year-on-year growth — revenue +22.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 13.8%, profit CAGR 23.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 13.81% |
| 1 Year: | 22.10% |
Compounded Profit Growth
| 5 Years: | 23.18% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +28.88% |
| 6 Months: | -26.55% |
| 3 Months: | -4.38% |
| 1 Month: | +3.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)46.55 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 13.8% over 5 years.
- Profit CAGR of 23.2% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 36.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KRMD KORU Medical Systems, Inc. R2K | 4.15 | -83.00 | $190.62M | 0.00% | -14.86% | -13.70% | 13.81% | 23.18% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Nov 2013 | May 2014 | Aug 2014 | Nov 2014 | May 2015 | Aug 2015 | Nov 2015 | May 2016 | Jun 2016 | Aug 2016 | Sep 2016 | Nov 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.03M | 4.50M | 4.55M | 4.97M | 5.35M | 6.62M | 6.33M | 7.71M | 6.08M | 5.43M | 5.53M | 6.04M | 6.24M | 6.55M | 7.76M | 7.39M | 6.94M | 7.00M | 8.20M | 8.43M | 8.18M | 9.64M | 10.19M | 10.40M | 11.76M |
| Gross Profit | - | 1.53M | 1.64M | 1.58M | 1.52M | 2.01M | 2.11M | 1.94M | 1.79M | 1.95M | 2.03M | 2.06M | 2.10M | 2.30M | 2.38M | 2.47M | 2.74M | 2.89M | 3.05M | 3.48M | 4.38M | 3.79M | 4.91M | 3.94M | 3.23M | 3.21M | 3.50M | 3.62M | 3.35M | 4.32M | 4.15M | 3.89M | 4.34M | 5.10M | 5.48M | 5.19M | 6.05M | 6.48M | 6.26M | 7.23M |
| Operating Income | 240.61K | 241.10K | 319.06K | 134.43K | -78.86K | 506.78K | 290.21K | -369.60K | -461.46K | -118.96K | -227.60K | -112.47K | 206.06K | 190.34K | 392.38K | 501.13K | 617.01K | 482.69K | -115.04K | 35.88K | 824.48K | 582.82K | -1.03M | 358.83K | -2.21M | -1.38M | -1.32M | -3.13M | -3.61M | -1.53M | -3.06M | -3.22M | -1.79M | -1.96M | -1.19M | -1.70M | -1.25M | -312.65K | -867.68K | -864.92K |
| Net Income | 161.95K | 158.06K | 202.99K | 92.69K | -64.64K | 335.21K | 167.55K | -233.31K | -320.21K | -82.61K | -153.21K | -104.28K | 126.95K | 148.47K | 265.75K | 403.43K | 475.72K | 386.55K | -85.39K | 78.18K | 651.81K | 449.43K | -1.08M | 249.18K | -1.28M | -1.12M | -1.09M | -2.54M | -2.92M | -1.23M | -2.41M | -2.50M | -1.37M | -1.94M | -988.72K | -1.58M | -1.17M | -206.87K | -777.97K | -807.08K |
| Diluted EPS | 0.00 | - | 0.01 | - | - | 0.01 | - | -0.01 | -0.01 | 0.00 | - | - | - | - | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.02 | 0.01 | -0.03 | 0.01 | -0.03 | -0.03 | -0.02 | -0.06 | -0.07 | -0.03 | -0.05 | -0.05 | -0.03 | 0.04 | 0.02 | 0.03 | -0.03 | 0.00 | 0.02 | -0.02 |
| R&D Expense | 50.86K | 131.40K | 158.42K | 116.89K | 53.66K | 38.71K | 51.56K | 56.67K | 57.40K | 67.69K | 75.20K | 59.14K | 45.91K | 24.84K | 14.85K | 9.85K | 23.96K | 126.92K | 101.96K | 178.24K | 170.26K | 256.02K | 298.20K | 390.42K | 336.84K | 386.88K | 800.02K | 1.15M | 1.30M | 862.15K | 1.56M | 1.60M | 1.29M | 1.48M | 1.13M | 1.53M | 1.11M | 1.19M | 933.11K | 1.32M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Feb 2011 | Feb 2012 | Feb 2013 | Feb 2014 | Feb 2015 | Feb 2016 | Feb 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.92M | 6.39M | 7.76M | 8.70M | 11.24M | 12.25M | 12.29M | 13.31M | 17.35M | 23.16M | 24.18M | - | 27.90M | 28.52M | 33.65M | 41.13M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 12.53M | 11.81M | 12.31M | 15.52M |
| Gross Profit | - | - | - | 5.31M | 6.69M | 7.60M | 7.57M | 8.14M | 10.81M | 14.85M | 14.94M | - | 15.37M | 16.71M | 21.33M | 25.60M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 26.15M | 26.98M | 27.78M | 28.58M |
| Operating Income | 1.19M | 1.29M | 1.06M | 1.01M | 1.15M | 1.18M | -736.25K | 1.24M | 1.16M | 585.68K | -1.25M | - | -10.78M | -10.27M | -6.45M | -2.97M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -10.19M | -9.40M | -5.56M | -2.16M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -10.68M | -9.77M | -6.06M | -2.62M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | -2.01M | 3.97M | 2.89K | 21.89K |
| Net Income | 704.09K | 815.89K | 725.76K | 703.43K | 753.12K | 782.86K | -535.00K | 904.96K | 910.57K | 564.35K | -1.21M | - | -8.66M | -13.74M | -6.07M | -2.64M |
| Diluted EPS | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | -0.01 | 0.02 | 0.02 | 0.01 | -0.03 | - | -0.19 | -0.30 | -0.13 | -0.06 |
| R&D Expense | 35.52K | 90.33K | 147.58K | 218.15K | 468.15K | 207.28K | 237.49K | 50.59K | 241.12K | 740.48K | 1.30M | 2.47M | 4.96M | 5.74M | 5.26M | 4.39M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Feb 2010 | Feb 2011 | Feb 2012 | Feb 2013 | Feb 2014 | Feb 2015 | Feb 2016 | Feb 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 3.43M | 4.81M | 5.59M | 6.21M | 7.28M | 8.39M | 8.17M | 9.28M | 10.55M | 13.88M | 39.92M | 41.29M | 42.33M | 28.46M | 27.22M | 28.20M |
| Total Equity | 1.69M | 2.48M | 3.55M | 4.36M | 5.19M | 6.27M | 7.12M | 6.68M | 7.67M | 8.96M | 11.24M | 36.16M | 36.50M | 31.33M | 20.35M | 16.81M | 17.05M |
| Cash & Equivalents | 813.38K | 1.32M | 1.76M | 1.93M | 2.23M | 2.56M | 4.20M | 3.31M | 3.97M | 3.74M | 5.87M | 27.32M | 25.33M | 17.41M | 11.48M | 9.58M | 8.87M |
| Long Term Debt | - | - | 439.31K | 393.86K | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 954.23K | 1.25M | 1.24M | 1.02M | 1.01M | 1.28M | 1.49M | 1.61M | 1.58M | 2.65M | 3.76M | 4.79M | 11.01M | 8.11M | 10.40M | 11.15M |
| Current Liabilities | - | 314.05K | 558.85K | 525.36K | 771.90K | 691.66K | 1.11M | 1.39M | 1.59M | 1.58M | 2.41M | 3.67M | 4.79M | 6.96M | 4.45M | 7.20M | 8.19M |
Cash Flows (Annual)
Figures in USD.
| Metric | Feb 2011 | Feb 2012 | Feb 2013 | Feb 2014 | Feb 2015 | Feb 2016 | Feb 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.03M | 560.60K | 784.79K | 954.39K | 826.10K | - | - | 899.91K | 1.48M | 320.62K | -743.32K | -4.32M | -5.40M | -4.89M | -319.72K | 462.40K |
| Investing Cash Flow | -353.37K | -339.06K | -568.20K | -218.00K | -744.98K | - | - | -219.28K | -1.73M | 1.31M | -1.04M | -366.17K | -2.80M | -814.60K | -1.33M | -949.79K |
| Financing Cash Flow | -166.23K | 213.44K | -43.49K | -439.31K | 248.72K | - | - | -19.36K | 14.43K | 501.30K | 23.22M | 2.71M | 279.49K | -218.87K | -248.53K | -221.35K |
| Capital Expenditure | -200.52K | -236.24K | -563.57K | -188.69K | -591.41K | -121.78K | -203.12K | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | 827.94K | 324.37K | 221.22K | 765.70K | 234.69K | - | - | - | - | - | - | - | - | - | - | - |
| Share Buybacks | - | - | - | - | 24.28K | - | - | - | - | 2.82K | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Feb 2011 | Feb 2012 | Feb 2013 | Feb 2014 | Feb 2015 | Feb 2016 | Feb 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 61.0% | 59.5% | 62.1% | 61.6% | 61.1% | 62.3% | 64.1% | 61.8% | - | 55.1% | 58.6% | 63.4% | 62.3% |
| Operating Margin % | 24.3% | 20.2% | 13.7% | 11.6% | 10.2% | 9.6% | -6.0% | 9.3% | 6.7% | 2.5% | -5.2% | - | -38.6% | -36.0% | -19.2% | -7.2% |
| Net Margin % | 14.3% | 12.8% | 9.3% | 8.1% | 6.7% | 6.4% | -4.4% | 6.8% | 5.2% | 2.4% | -5.0% | - | -31.0% | -48.2% | -18.0% | -6.4% |
| ROE % | 28.4% | 23.0% | 16.7% | 13.5% | 12.0% | 11.0% | -8.0% | 11.8% | 10.2% | 5.0% | -3.4% | - | -27.6% | -67.5% | -36.1% | -15.5% |
| ROCE % | 38.3% | 30.4% | 21.0% | 18.5% | 17.4% | 16.2% | -10.9% | 16.1% | 13.0% | 5.1% | -3.5% | - | -30.5% | -42.8% | -32.2% | -14.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | First Light Asset Management, LLC | 9.45% | 3.77M | $17.05M |
| 2 | Topline Capital Management, LLC | 8.81% | 3.51M | $15.90M |
| 3 | Blackrock Inc. | 5.95% | 2.37M | $10.73M |
| 4 | Vanguard Capital Management LLC | 4.23% | 1.69M | $7.63M |
| 5 | Geode Capital Management, LLC | 2.64% | 1.05M | $4.76M |
| 6 | Simcoe Capital LLC | 2.03% | 811.25K | $3.67M |
| 7 | Meros Investment Management, Lp | 1.91% | 760.45K | $3.44M |
| 8 | Empire Financial Management Company, LLC | 1.76% | 703.14K | $3.18M |
| 9 | State Street Corporation | 1.63% | 649.23K | $2.94M |
| 10 | Archon Capital Management LLC | 1.61% | 642.92K | $2.91M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KRMD
[Form 4/A] KORU Medical Systems, Inc. Amended Insider Trading Activity - Stock Titan
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQSTk0NEk5RXllakNiVFJoWXJ0UExaU1dGZWFBbzdla29zaHdSUEJUUkVETXkxVVFXWGRWTGlDTkVLa2RqTk4ydVRyX2hYOVdzZXlmaFNNdXB3a0ZrTU9IT2JFRzIwU3BMUFg2ZC16NUQ5SS1INnh0QWp0SkYxdW9iZUxVMVlMSlJEeUNsR1…
We Think KORU Medical Systems (NASDAQ:KRMD) Can Easily Afford To Drive Business Growth - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOUUNLLVhyMjhVRVpXbFQzY3FLQktBRzdDVWxQTlpmbEEzdTNzSFI1QlE2d0ctaGxZLTJYaGlZMmNjcThpSW5lTkVNelZFLWhlekhkVUtVeTFNNS1oN2Y1QjVycWFlRkhMM1c4ZFp5OTh0YzNpSV92TnBCUFN5YWR6cjZWWGdwT0VMMTNNMT…
KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Shares Climb 34% But Its Business Is Yet to Catch Up - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxNWHI0WDd5T25nR1NYcjFpTDl3NGxPN0tFUEhObmhZM3pvR2xzLTBqMDNWWGJzelN6UENHdjRkWmNRT0xfNTY1T1BlU0lmV2toX3ZfWnVfSVVPNVkxNlQ1VVdxM3VqMURFR29hNXJOc3FleEJzUWhxYmw2aEhfaHN4TVZZTFR1cWh2bDJUYn…
Insider Purchase: Chief Executive Officer of $KRMD Buys 1,191 Shares | KRMD Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNNXZ2LTNheWI4dTZCcy1BVXBMY2dDcDlGbEUwT3RQcUFaUlNrcHMweHZ4Y2NEcGJ5dWlQdXV2eDZwUzlqZ1ZuRVh3VG0tOXJVWEI4cmlxYmZoOEl1eThRY2lFSjB2YThEMXZaQ3VQdG5vUHZGek5lQU1hQi1uemxEV1QzbmEwYncybFJNTF…
KORU Medical (KRMD) director Matin Shahriar receives 3,571-share stock grant - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPN01SeHBaaVVIT1ZxV0JVWDdJNExLa1g0TjV4Qy1zWjdUUHlyU3NNQmxSZWtKMG9BUTBaaWhwM0ltMmNiLVd0UHdHeU1Jb3ZBS3YyZGdMT2MyS25ESWpfbWhfN2VIUHVRZ2JVRnJOaDdYeUhvaFkybFp3TXZ5UTU3VGFMX2FiUm41ZGFieE…
KORU Medical Systems, Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxONEt4eFNGZF9oYlZ1Q1dEbEc3LUdENjZaSzc4akctcUR6ck02QThPTDlRQXRNanpmc0NIUzVXdFlidVhKSW5kTlhKaGNWcEN3a3hDLWtTUy1kSThFdjRneWdkVVk5MmVaVklydzNwbThXRzVaUFFsUWZCelYzQXdfNFM2TEIzNmpNX3MwSz…
KRMD — Frequently Asked Questions
What is the current share price of KORU Medical Systems, Inc. (KRMD)?
As of 2026-07-14 21:23 PDT, KORU Medical Systems, Inc. (KRMD) trades at $4.15 on NasdaqCM. Its 52-week range is $2.94 to $6.52.
What is the market capitalisation of KRMD?
KORU Medical Systems, Inc. (KRMD) has a market capitalisation of $190.62M on NasdaqCM.
What is the P/E ratio of KRMD?
KRMD trades at a trailing price-to-earnings (P/E) ratio of -83.00. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 10.90.
What is the return on equity (ROE) of KRMD?
KRMD has a return on equity (ROE) of -13.70%. Its return on capital employed (ROCE) is -14.86%.
Is KRMD a good stock to buy?
This page provides a data-driven analysis of KORU Medical Systems, Inc. (KRMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.